Radioimmunoassay: Difference between revisions
Feedback

From WikiLectures

(original text taken from WS radioimunoanalýza)
 
(translate to english)
Line 1: Line 1:
'''Radioimunoanalýza (RIA)''' neboli '''radioimunologická stanovení''' zahrnují takové metody radioizotopové mikroanalýzy, jejichž základem je imunochemická reakce [[antigen]]u se specifickou [[protilátka|protilátkou]] (Ab), prováděná in vitro v přítomnosti vhodné radioaktivně značené sloučeniny jako radioindikátoru, který umožňuje kvantifikaci stanovení na základě určení distribuce aktivity.<ref name="test">{{Cite
'''Radioimmunoassay (RIA)''' or '''radioimmunological assays''' include such methods of radioisotope microanalysis, that their basis of is the immunochemical reaction of an antigen with a specific antibody (Ab), and which is carried out in vitro in the presence of a suitable radiolabeled compound as a radioindicator, which allows the quantification of the assay based on the determination of the activity distribution.<ref name="test">{{Cite
| type = web
| type = web
| surname1 = -
| surname1 = -
Line 8: Line 8:
,</ref>
,</ref>


== Historie ==
== History ==
Metoda, pomocí které byla poprvé změřena hladina [[inzulin]]u v krvi in vitro, byla vyvinuta v 50. letech 20. století v USA. Jednalo se vůbec o první kvantitativní stanovení hladiny [[hormon]]u v krvi. Za tento objev obdržela Rosalyn Sussman Yalow v roce 1977 Nobelovu cenu za medicínu. Tím, že bylo možné přesně změřit hladinu inzulinu v krvi, se léčba [[Diabetes mellitus|diabetu mellites]] posunula o výrazný kus dopředu.<br />
The method by which the blood insulin was first measured in vitro was developed in the 1950s in the USA. It was the first ever quantitative determination of the level of the hormone in the blood. For this discovery, Rosalyn Sussman Yalow received the Nobel Prize in Medicine in 1977. By being able to accurately measure the level of insulin, the treatment of diabetes mellitus has moved up a significant step forward.


== Princip metody ==
== The principle of the method ==
Jedná se o kompetitivní imunoreakci, tzn. značený antigen soupeří o vazebná místa na protilátce, která se v reakční směsi nachází v omezeném množství, s neznačeným antigenem. Stanovovaná látka je v tomto případě neznačený antigen, další antigen je značen např. radioaktivním izotopem iodu (<sup>125</sup>I,<sup>131</sup>I) pro proteinové antigeny, či tritiem nebo <sup>14</sup>C pro nízkomolekulární látky. Výsledkem reakce je vznik dvou komplexů: značený antigen-protilátka (Ag*-Ab) a neznačený antigen-protilátka (Ag-Ab). Množství značeného komplexu (Ag*-Ab) je nepřímo úměrné množství stanovovaného antigenu, čili čím více stanovované látky se ve vzorku nachází, tím menší množství značeného komplexu vznikne a tím menší bude výsledný signál. Toto si lze jednoduše vysvětlit tím, že značené antigeny se nenavážou na protilátku pro nedostatek vazebných míst, která obsadí neznačený antigen. Z uvedených poznatků také vyplývá, že se v reakční směsi nacházejí i volné formy Ag a Ag*. Celková reaktivita (T) se tak rozdělí do dvou frakcí vázané (B) a volné (F), přičemž platí: T = B + F.
It is a competitive immunoreaction, i.e. the labeled antigen competes with the unlabeled antigen for binding sites on the antibody, which is present in a limited amount in the reaction mixture. In this case, the determined substance is an unlabeled antigen, another antigen is labeled, for example, with a radioactive isotope of iodine ( 125 I, 131 I) for protein antigens, or with tritium or 14C for low molecular weight substances. The result of the reaction is the formation of two complexes: labeled antigen-antibody (Ag*-Ab) and unlabeled antigen-antibody (Ag-Ab). The amount of the labeled complex (Ag*-Ab) is inversely proportional to the amount of the determined antigen, i.e. the more the determined substance is in the sample, the smaller the amount of the labeled complex will be and the smaller the resulting signal will be. This can be simply explained by the fact that the labeled antigens do not bind to the antibody due to the lack of binding sites to occupy the unlabeled antigen. From the above findings, it also leads to that free forms of Ag and Ag* are also found in the reaction mixture. The total reactivity (T) is thus divided into two fractions bound (B) and free (F), while the following applies: T = B + F.


== Postup metody ==
== Method prodecedure ==
Pro kvantitativní stanovení určité látky ve vyšetřovaném vzorku je třeba vytvořit kalibrační křivku, která odráží závislost výsledného signálu na známé [[koncentrace|koncentraci]] dané látky. Kalibrační křivku připravujeme z tzv. standardů. Nedílnou součástí stanovení jsou i kontroly, kde předem známe velikost [[radioaktivita|radioaktivity]].
For the quantitative determination of certain substance in the examined sample, it is necessary to create a calibration curve that reflects the depedence of the resulting signal on the known concetration of the given substance. We prepare the calibration curve from the so-called standards. Controls, where we know the amount of radioactivity in advance, are an integral part of the determination.  


'''Solid-phase RIA (ve zkumavkách)'''
'''Solid-phase RIA (in tubes)'''
# Do zkumavek potažených specifickou protilátkou napipetujeme jednotlivé standardy a neznámé vzorky. Kontroly napipetujeme do nepotahovaných zkumavek.
# Invidual standards and unknown samples are pipetted into test tubes coated with a specific antibody. The control samples are pipetted into the uncoated tubes.
# Do každé zkumavky přidáme ve stejném množství radioindikátor (Ag*).
# Add the same amount of radioindicator (Ag*) to each test tube.
# Promícháme a necháme inkubovat.
# Mix and let it incubate.  
# Po dostatečně dlouhé době odsajeme reakční směs.
# After a sufficiently long time, we aspirate the reaction mixture.
# Měříme vázanou (B) a volnou (F) radioaktivitu na gamačítači.
#We measure bound (B) and free (F) radioactivity on a gamma counter.  


Pozn.: Separaci imunokomplexu lze provést i jinými způsoby, např. pomocí [[elektroforéza|elektroforézy]], ionexové [[chromatografie]] atd.<br />
Note: Separation of the immunocomplex can also be done in other ways, e.g. using electrophoresis , ion exchange chromatography , etc.<br />
=== Příklady využití RIA v praxi <ref name="test1">{{Cite
=== Examples of the use of RIA in practice <ref name="test1">{{Cite
| type = web
| type = web
| surname1 = -
| surname1 = -
Line 33: Line 33:
}},</ref> ===
}},</ref> ===


* endokrinologie (hladiny hormonů) v krvi
* endocrinology (hormone levels in the blood)
* digitoxin nebo digoxin u pacientů, kteří berou tyto léky
* digitoxin or digoxin in of patients taking these drugs
* toxikologie: průkaz přítomnosti drog
* toxicology: evidence of the presence of drugs
* krevní [[transfuze]]: přítomnost povrchového antigenu [[hepatitida B|hepatitidy B]] (HBsAg) v darované krvi
* blood transfusion: presence of hepatitis B surface antigen (HBsAg) in donated blood
* imunologie: anti-DNA protilátky u systémového lupus erythematosus ([[SLE]]).
* imunology: anti-DNA antibodies in systemic lupus erythematosus (SLE)  
=== Výhody a nevýhody RIA ===
=== Advantages and disadvantages of RIA ===
Hlavními výhodami této metody jsou vysoká citlivost a možnost automatizace. Nevýhodou je nutnost separačního mezistupně, dále nákladné zařízení nutné pro provádění této metody a v neposlední řadě rizika spojená s manipulací s radioaktivní látkou.
The main advantages of this method are high sensitivity and the possibility of automation. The disadvantage is the necessity of an intermediate separation stage, the expensive equipment required to perform this method and, last but not least, the risks associated with handling the radioactive substance.


<noinclude>
<noinclude>

Revision as of 19:05, 17 December 2022

Radioimmunoassay (RIA) or radioimmunological assays include such methods of radioisotope microanalysis, that their basis of is the immunochemical reaction of an antigen with a specific antibody (Ab), and which is carried out in vitro in the presence of a suitable radiolabeled compound as a radioindicator, which allows the quantification of the assay based on the determination of the activity distribution.[1]

History

The method by which the blood insulin was first measured in vitro was developed in the 1950s in the USA. It was the first ever quantitative determination of the level of the hormone in the blood. For this discovery, Rosalyn Sussman Yalow received the Nobel Prize in Medicine in 1977. By being able to accurately measure the level of insulin, the treatment of diabetes mellitus has moved up a significant step forward.

The principle of the method

It is a competitive immunoreaction, i.e. the labeled antigen competes with the unlabeled antigen for binding sites on the antibody, which is present in a limited amount in the reaction mixture. In this case, the determined substance is an unlabeled antigen, another antigen is labeled, for example, with a radioactive isotope of iodine ( 125 I, 131 I) for protein antigens, or with tritium or 14C for low molecular weight substances. The result of the reaction is the formation of two complexes: labeled antigen-antibody (Ag*-Ab) and unlabeled antigen-antibody (Ag-Ab). The amount of the labeled complex (Ag*-Ab) is inversely proportional to the amount of the determined antigen, i.e. the more the determined substance is in the sample, the smaller the amount of the labeled complex will be and the smaller the resulting signal will be. This can be simply explained by the fact that the labeled antigens do not bind to the antibody due to the lack of binding sites to occupy the unlabeled antigen. From the above findings, it also leads to that free forms of Ag and Ag* are also found in the reaction mixture. The total reactivity (T) is thus divided into two fractions – bound (B) and free (F), while the following applies: T = B + F.

Method prodecedure

For the quantitative determination of certain substance in the examined sample, it is necessary to create a calibration curve that reflects the depedence of the resulting signal on the known concetration of the given substance. We prepare the calibration curve from the so-called standards. Controls, where we know the amount of radioactivity in advance, are an integral part of the determination.

Solid-phase RIA (in tubes)

  1. Invidual standards and unknown samples are pipetted into test tubes coated with a specific antibody. The control samples are pipetted into the uncoated tubes.
  2. Add the same amount of radioindicator (Ag*) to each test tube.
  3. Mix and let it incubate.
  4. After a sufficiently long time, we aspirate the reaction mixture.
  5. We measure bound (B) and free (F) radioactivity on a gamma counter.

Note: Separation of the immunocomplex can also be done in other ways, e.g. using electrophoresis , ion exchange chromatography , etc.

Examples of the use of RIA in practice [2]

  • endocrinology (hormone levels in the blood)
  • digitoxin or digoxin in of patients taking these drugs
  • toxicology: evidence of the presence of drugs
  • blood transfusion: presence of hepatitis B surface antigen (HBsAg) in donated blood
  • imunology: anti-DNA antibodies in systemic lupus erythematosus (SLE)

Advantages and disadvantages of RIA

The main advantages of this method are high sensitivity and the possibility of automation. The disadvantage is the necessity of an intermediate separation stage, the expensive equipment required to perform this method and, last but not least, the risks associated with handling the radioactive substance.


Links

Related articles

External links

Reference

  1. -,. Radioimunoanalýza (RIA) [online]. [cit. 2013-05-18]. <http://orion.sci.muni.cz/virtuallab/dokumenty/pdf/Radioimunoanalyza.pdf>. ,
  2. -,. Imunoreakce se značenými protilátkami [online]. [cit. 2013-05-18]. <http://imunologie.lf2.cuni.cz/soubory_vyuka/imunoreakce.pdf>. ,